Cervera CH, Torres CV

Idioma: Español
Referencias bibliográficas: 40
Paginas: 243-245
Archivo PDF: 123.86 Kb.

RESUMEN

La policondritis recidivante es una enfermedad rara que afecta tejidos cartilaginosos como pabellones auriculares, nariz, estructuras laringotraqueales y articulaciones, entre otros. El tratamiento habitual de la enfermedad consiste en el uso de corticos-teroides y antiinflamatorios tradicionales como aspirina e indometacina. Describimos un caso de policondritis recidivante en un hombre diabético de 82 años de edad, cuyas condiciones particu-lares obligaron a utilizar metotrexate y celecoxib como tratamiento alternativo, el cual fue exitoso.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Luthra HS. Relapsing polychondritis. En: Klippel JH, Dieppe P, editors. Rheumatology. Barcelona, Spain:Mosby; 1998.

2. McAdam LP, O’Hanlan MA, Bluestone R, Pearson CM. Relapsing polychondritis. Prospective study of 23 patients and review of the literature. Medicine

3. 1976;55:193-215.

4. Kent PD, Michet CJ, Luthra HS. Relapsing polychondritis. Curr Opin Rheumatol 2004;16:56-61.

5. Meza J, Remes JM, Montaño A. Policondritis recidivante. Presentación de 5 casos y revisión de la literatura. Rev Mex Reumatol 2001;16:309-314.

6. Letko E, Zafirakis P, Baltatzis S, et al. Relapsing polichondritis: a clinical review. Semin Arthritis Rheum 2002;31:384-395.

7. Trentham ED, Le HC. Relapsing polychondritis. Ann Intern Med 1998;129:114-122.

8. Sane CD, Vidaillet JH, Burton SC. Cutaneous signs of cariopulmonary disease. Saddle nose, red ears, and fatal airway collapse. Chest 1987;91:268-270.

9. Orme LR, Nordlund JJ, Barich L, et al. The magic syndrome (mouth and genital ulcers with inflamed cartilage). Arch Dermatol 1990;126:940-944.

10. Stewart SS, Ashizawa T, Dudley WA, Goldberg JW, Lidsky MD. Cerebral vasculitis in relapsing polychondritis. Neurology 1988;38:150-152.

11. Wilke SW. Methotrexate use in miscellaneous inflammatory diseases. Rheumatic Dis Clin N Am 1997;23: 855-882.

12. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune

13. mediated inflammatory diseases (May 2003). Ann Rheum Dis 2003;62(Suppl II):ii2-ii9.

14. Aletaha D, Kapral T, Smolen JS. Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. Ann Rheum Dis 2003;62:482-486.

15. Hoekstra M, van Ede AE, Haagsma CJ, et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann

16. Rheum Dis 2003;62:423-426.

17. Lang B, Rothenfusser A, Lanchbury SJ, Rauh G, Breedveld FC, Urlacher A, et al. Susceptibility to relapsing polychondritis is associated with HLA-DR4. Arthritis Rheum 1993;36:660-664.

18. Neild GH, Cameron JS, Lessof MH, Ogg CS, Turner DR. Relapsing polychondritis with crescentic glomerulonephritis. Br Med J 1978;1:743-745.

19. Sundaramam MBM, Rajput AH. Nervous system complications of relapsing polychondritis. Neurology 1983;33:513-515.

20. Lifshitz GA, Ibarra GF, García JL, Malváez VM, Halabe CJ. Policondritis recidivante: informe de siete casos. Rev Med IMSS 1986;24:387-392.

21. Michet JC, McKenna CH, Luthra SH, O’Fallon WM. Relapsing polychondritis. Survival and predictive role of early disease manifestations. Ann Intern Med 1986;

22. 104:74-78.

23. Luthra HS. Relapsing polychondritis. En: Klippel JH, Dieppe P, editors. Rheumatology. Barcelona, Spain:Mosby; 1998.

24. McAdam LP, O’Hanlan MA, Bluestone R, Pearson CM. Relapsing polychondritis. Prospective study of 23 patients and review of the literature. Medicine 1976;55:193-215.

25. Kent PD, Michet CJ, Luthra HS. Relapsing polychondritis. Curr Opin Rheumatol 2004;16:56-61.

26. Meza J, Remes JM, Montaño A. Policondritis recidivante. Presentación de 5 casos y revisión de la literatura. Rev Mex Reumatol 2001;16:309-314.

27. Letko E, Zafirakis P, Baltatzis S, et al. Relapsing polichondritis: a clinical review. Semin Arthritis Rheum 2002;31:384-395.

28. Trentham ED, Le HC. Relapsing polychondritis. Ann Intern Med 1998;129:114-122.

29. Sane CD, Vidaillet JH, Burton SC. Cutaneous signs of cariopulmonary disease. Saddle nose, red ears, and fatal airway collapse. Chest 1987;91:268-270.

30. Orme LR, Nordlund JJ, Barich L, et al. The magic syndrome (mouth and genital ulcers with inflamed cartilage). Arch Dermatol 1990;126:940-944.

31. Stewart SS, Ashizawa T, Dudley WA, Goldberg JW, Lidsky MD. Cerebral vasculitis in relapsing polychondritis. Neurology 1988;38:150-152.

32. Wilke SW. Methotrexate use in miscellaneous inflammatory diseases. Rheumatic Dis Clin N Am 1997;23: 855-882.

33. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). Ann Rheum Dis 2003;62(Suppl II):ii2-ii9.

34. Aletaha D, Kapral T, Smolen JS. Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. Ann Rheum Dis 2003;62:482-486.

35. Hoekstra M, van Ede AE, Haagsma CJ, et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:423-426.

36. Lang B, Rothenfusser A, Lanchbury SJ, Rauh G, Breedveld FC, Urlacher A, et al. Susceptibility to relapsing polychondritis is associated with HLA-DR4. Arthritis Rheum 1993;36:660-664.

37. Neild GH, Cameron JS, Lessof MH, Ogg CS, Turner DR. Relapsing polychondritis with crescentic glomerulonephritis. Br Med J 1978;1:743-745.

38. Sundaramam MBM, Rajput AH. Nervous system complications of relapsing polychondritis. Neurology 1983;33:513-515.

39. Lifshitz GA, Ibarra GF, García JL, Malváez VM, Halabe CJ. Policondritis recidivante: informe de siete casos. Rev Med IMSS 1986;24:387-392.

40. Michet JC, McKenna CH, Luthra SH, O’Fallon WM. Relapsing polychondritis. Survival and predictive role of early disease manifestations. Ann Intern Med 1986; 104:74-78.